SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.3746070553104782,0.6253929446895216
CC(=O)[O-],_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.12596923795689038,0.8740307620431096
CC(=O)[O-],_ACETATE,DEPRESSION,NCT02837432,Early Phase 1,0.15169157893758087,0.8483084210624189
CC(=O)[O-],_ACETATE,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT04002934,Phase 2,0.13380960540916972,0.8661903945908302
CC(=O)[O-],_ACETATE,HIV-1 INFECTION,NCT03536234,Phase 2,0.08270021213516214,0.9172997878648378
CC(=O)[O-],_ACETATE,BURN,NCT01413620,Phase 1,0.1567035776997949,0.8432964223002051
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.8463331698171883,0.1536668301828116
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.13330977895187096,0.8666902210481291
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,_GOSERELIN,BREAST NEOPLASM,NCT01723774,Phase 2,0.31665822995600884,0.6833417700439911
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.18216811640419267,0.8178318835958072
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.0061499651908042225,0.9938500348091956
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.006692141550090502,0.9933078584499094
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.004840344698293651,0.9951596553017064
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.0024186665672255273,0.9975813334327744
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,VASCULITIS,NCT03692416,Phase 3,0.006692141550090502,0.9933078584499094
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,IDIOPATHIC MEMBRANOUS NEPHROPATHY,NCT03549663,Not Applicable,0.0005668697154286753,0.9994331302845711
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,AIRWAY INFLAMMATION,NCT03861390,Phase 1|Phase 2,0.0469964986880199,0.9530035013119801
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.21264742806181047,0.7873525719381892
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,_ABIRATERONE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.636180643352151,0.3638193566478492
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,_FLUTAMIDE,PCOS,NCT00930228,Phase 1,0.23868365078870035,0.7613163492112994
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASMS,NCT03693612,Phase 2,0.7102504370912951,0.2897495629087056
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,CASTRATION-RESISTANT PROSTATIC CANCER,NCT04404140,Phase 1,0.4909731774408644,0.5090268225591356
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.41848974963519786,0.5815102503648022
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.3227649163099406,0.6772350836900596
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACYCLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.06164838352403752,0.9383516164759624
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACICLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.06164838352403752,0.9383516164759624
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.2644977733183417,0.7355022266816583
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.3439438356770506,0.6560561643229491
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.31197264995206825,0.6880273500479318
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.11076303441025227,0.8892369655897475
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.058995277175276535,0.9410047228247234
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.0005668697154286754,0.9994331302845714
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.0042981683390073714,0.9957018316609928
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.0831491838842241,0.916850816115776
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,GRAFT VS HOST DISEASE,NCT03357159,Phase 2,0.04113595138268799,0.958864048617312
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,HEPATOCELLULAR CARCINOMA,NCT04011033,Phase 2|Phase 3,0.0042981683390073714,0.9957018316609928
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,MULTIPLE SCLEROSIS,NCT03477500,Phase 3,0.004840344698293652,0.9951596553017064
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,DIFFUSE LARGE B CELL LYMPHOMA,NCT04214626,Phase 2,0.03071746933993696,0.9692825306600628
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,VASCULITIS,NCT03692416,Phase 3,0.0015715795733936562,0.9984284204266064
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.008885049817569051,0.9911149501824309
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.028907080887565526,0.9710929191124344
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,PERIPHERAL T CELL LYMPHOMA,NCT03321890,Phase 2,0.03071746933993696,0.9692825306600628
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,JUVENILE IDIOPATHIC ARTHRITIS,NCT04169828,Not Applicable,0.0015715795733936562,0.9984284204266064
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,ACUTE MYELOID LEUKEMIA,NCT03467386,Phase 1,0.22537146978103376,0.7746285302189664
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,LYMPHEDEMA,NCT04390685,Phase 1|Phase 2,0.010544437006750269,0.9894555629932495
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,LYMPHOMA,NCT03151876,Phase 2,0.1291152165610402,0.8708847834389597
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,HIV INFECTIONS|AIDS,NCT03517631,Phase 1,0.11160525188562004,0.8883947481143798
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.17222070296047715,0.8277792970395227
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.13686306883078456,0.8631369311692155
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,GRAFT VS HOST DISEASE,NCT03263767,Phase 2,0.07747931792340892,0.9225206820765912
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,HEPATOCELLULAR CARCINOMA,NCT02905188,Phase 1,0.2414635667748247,0.7585364332251753
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,PERIPHERAL T CELL LYMPHOMA,NCT04083495,Phase 2,0.2414635667748247,0.7585364332251753
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.470413654273569,0.529586345726431
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,OVARIAN CANCER,NCT03936270,Phase 2,0.6876762744053586,0.3123237255946413
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,PROSTATE CANCER,NCT02905318,Phase 2,0.706364787893313,0.2936352121066869
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,_RIBOCICLIB,BREAST NEOPLASM,NCT03283384,Phase 2,0.5189301519330533,0.4810698480669468
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.6360104476841356,0.36398955231586455
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,_VINORELBINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.5924842031848612,0.4075157968151389
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.050067737996700806,0.9499322620032989
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.08644477343344809,0.9135552265665516
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04182204,Phase 3,0.15260389849509626,0.8473961015049036
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,NK/T CELL LYMPHOMA,NCT04230330,Phase 1,0.14483067831662394,0.855169321683376
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,METASTATIC BREAST CANCER,NCT03901339,Phase 3,0.15260389849509626,0.8473961015049036
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.4478672291261416,0.5521327708738584
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,_EPIRUBICIN,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.07342652495351132,0.9265734750464886
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.3634515978438367,0.6365484021561629
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,OVARIAN CANCER,NCT03378297,Early Phase 1,0.28321170009716123,0.7167882999028385
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,BREAST NEOPLASM,NCT03740893,Phase 2,0.3570453024803568,0.6429546975196427
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER,NCT03810105,Phase 2,0.4156568856368865,0.5843431143631136
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,BREAST NEOPLASM,NCT03280563,Phase 1|Phase 2,0.5770000468101586,0.4229999531898415
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,MYELODYSPLASTIC SYNDROME,NCT02936752,Phase 1,0.9157033611661362,0.08429663883386382
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,ACUTE MYELOID LEUKEMIA,NCT01305499,Phase 2,0.4233209525830752,0.5766790474169248
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,_ENTINOSTAT,NEUROENDOCRINE TUMORS,NCT03211988,Phase 2,0.783292330097309,0.2167076699026912
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,_MITOXANTRONE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.09923251647308627,0.9007674835269138
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.0021185864763846422,0.9978814135236154
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PNEUMONIA,NCT03852537,Phase 2,0.016699770199926675,0.9833002298000733
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.14404423777140016,0.8559557622285997
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.047124353231294096,0.9528756467687058
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,"PAIN, CHRONIC",NCT02983682,Phase 3,0.2939066080687071,0.7060933919312927
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,CONTRACEPTION,NCT02799641,Not Applicable,0.06788377347160528,0.9321162265283948
O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+],_EOSIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04008017,,0.2621933825012744,0.7378066174987254
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.007256100468294097,0.9927438995317058
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,ACUTE MYELOID LEUKEMIA,NCT02782546,Phase 2,0.2978165710745808,0.7021834289254193
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.20194104324998088,0.798058956750019
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,DRY EYE,NCT04115800,Early Phase 1,0.08643896246694655,0.9135610375330532
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,ISCHEMIC HEART DISEASE,NCT03600961,,0.13447267274570165,0.8655273272542982
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,_CLADRIBINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03318419,Phase 2,0.10549538485850167,0.8945046151414984
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,_CLADRIBINE,LYMPHOMA,NCT03151876,Phase 2,0.11137689693883716,0.8886231030611629
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.33613686818444105,0.6638631318155588
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,MYELODYSPLASTIC SYNDROME,NCT03412266,Phase 2,0.06150471774243128,0.9384952822575688
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,_ELTROMBOPAG,ACUTE MYELOID LEUKEMIA,NCT03603795,Phase 2,0.16266004016486912,0.8373399598351307
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.13177007997920004,0.8682299200207999
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.4907630325611066,0.5092369674388935
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,ACUTE MYELOID LEUKEMIA,NCT02771197,Phase 2,0.4907630325611066,0.5092369674388935
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,_VEDOTIN,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04182204,Phase 3,0.4844455168566586,0.5155544831433414
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINCRISTINE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.1204262935798716,0.8795737064201282
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,DEPRESSION,NCT02837432,Early Phase 1,0.07197795477904044,0.9280220452209595
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.09617698053840834,0.9038230194615916
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.08821030517394889,0.9117896948260512
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,HIV INFECTION,NCT03237689,Early Phase 1,0.1303009232236863,0.8696990767763135
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.2868222505361713,0.7131777494638287
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,PROSTATIC NEOPLASMS,NCT04034095,,0.02228018252868074,0.9777198174713192
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,ASTHMA IN CHILDREN,NCT03962894,,0.08645807240498972,0.9135419275950104
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,CARDIAC SARCOIDOSIS,NCT03705884,Not Applicable,0.028099493734379626,0.9719005062656204
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.0021185864763846414,0.9978814135236154
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,_IDARUBICIN,HEPATOCELLULAR CARCINOMA,NCT04178642,Phase 2,0.1825515517968062,0.8174484482031937
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.07093876647770919,0.9290612335222908
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE MYELOMA,NCT04163107,Phase 1,0.11874253423619055,0.8812574657638095
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.1993560004329068,0.8006439995670932
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,TYPE 1 DIABETES,NCT03428945,Phase 2,0.050719993215982834,0.9492800067840172
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.39899625490909096,0.6010037450909089
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.07982239623519094,0.9201776037648091
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.20884093700370696,0.791159062996293
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03913559,Phase 2,0.27868912946851243,0.7213108705314875
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.0749796254265652,0.9250203745734348
CNNCc1ccc(C(=O)NC(C)C)cc1,_PROCARBAZINE,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT03495960,Phase 2,0.2530371583666972,0.7469628416333027
O=P1(NCCCl)OCCCN1CCCl,_IFOSFAMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03736616,Phase 2,0.18892492615345627,0.8110750738465436
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,NCT01376427,Not Applicable,0.010397049819712434,0.9896029501802877
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.016159467105776412,0.9838405328942236
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,NK/T CELL LYMPHOMA,NCT04230330,Phase 1,0.007960437682661376,0.9920395623173386
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,LYMPHOMA,NCT02436707,Phase 2,0.0037312986235786953,0.9962687013764212
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,GRAFT VS HOST DISEASE,NCT00391170,Phase 2,0.029925194494314782,0.9700748055056851
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,WALDENSTRÃ–M MACROGLOBULINEMIA,NCT04463953,Phase 2,0.016159467105776412,0.9838405328942236
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,CUSHING DISEASE,NCT03974789,,0.035562090981537016,0.9644379090184628
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,_SOMATOSTATIN,HEPATOCELLULAR CARCINOMA,NCT02799212,Phase 3,0.2976628283693853,0.7023371716306147
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,_CABERGOLINE,ENDOMETRIOSIS,NCT03928288,Phase 2,0.2972056824414632,0.7027943175585368
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MULTIPLE SCLEROSIS,NCT04035889,Not Applicable,0.4191016252750717,0.5808983747249283
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,IRRITABLE BOWEL SYNDROME,NCT04193501,Phase 3,0.5577168022824036,0.4422831977175965
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,RELAPSING REMITTING MULTIPLE SCLEROSIS,NCT03498131,Early Phase 1,0.4621979485492153,0.5378020514507846
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MIGRAINE DISORDERS,NCT03597529,Phase 2,0.5012691988757867,0.4987308011242134
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,_SERTRALINE,MYELODYSPLASTIC SYNDROME,NCT02452983,Phase 1,0.2638511313718228,0.7361488686281773
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,DELIRIUM,NCT04456985,Not Applicable,0.15205850232522464,0.8479414976747753
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.15901411581701164,0.8409858841829884
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,ANEMIA,NCT02757898,Phase 1,0.5164371953534989,0.4835628046465013
C[N+](C)(C)CCO,_CHOLINE,GESTATIONAL DIABETES,NCT04302168,Not Applicable,0.42914518227007664,0.5708548177299232
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,_AZITHROMYCIN,BACTERIAL INFECTIONS,NCT03925480,Phase 3,0.03782686077791826,0.9621731392220818
NC(=O)c1cccnc1,_NICOTINAMIDE,HYPERTENSION,NCT04112043,Phase 1,0.3744524552746215,0.6255475447253784
NC(=O)c1cccnc1,_NIACINAMIDE,HYPERTENSION,NCT04112043,Phase 1,0.3744524552746215,0.6255475447253784
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,BURN,NCT00985205,Phase 3,0.6538109453950264,0.3461890546049739
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,BURN,NCT00985205,Phase 3,0.6538109453950264,0.3461890546049739
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.5247521886796669,0.4752478113203331
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,SEPSIS,NCT04160676,Not Applicable,0.3021557623798198,0.6978442376201806
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,DELIRIUM,NCT04214106,,0.4210830330014244,0.5789169669985755
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,_AZACITIDINE,PERIPHERAL T CELL LYMPHOMA,NCT04480125,Phase 2,0.6827458460303931,0.3172541539696072
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT03495960,Phase 2,0.34783668092334663,0.6521633190766529
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,DIFFUSE LARGE B CELL LYMPHOMA,NCT04214626,Phase 2,0.07828206423844694,0.9217179357615528
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,MANTLE CELL LYMPHOMA,NCT04109872,,0.09253331507077026,0.9074666849292296
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04404283,Phase 3,0.07340182047074399,0.9265981795292559
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,_LENALIDOMIDE,NON HODGKIN LYMPHOMA,NCT02180711,Phase 1|Phase 2,0.11146124381348832,0.8885387561865115
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.42087525252290736,0.5791247474770926
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.4068777212031209,0.5931222787968791
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,LYMPHOMA,NCT02974647,Phase 2,0.31690051393589097,0.6830994860641091
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,HODGKIN LYMPHOMA,NCT03681561,Phase 1|Phase 2,0.5706919088315675,0.4293080911684327
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,METASTATIC BREAST CANCER,NCT04159818,Phase 2,0.14346191236393044,0.8565380876360694
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.18404738312820626,0.8159526168717933
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,MANTLE CELL LYMPHOMA,NCT03710772,Phase 2,0.5221571089697861,0.4778428910302139
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,ANXIETY,NCT02153944,Not Applicable,0.20376381230086785,0.7962361876991321
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,LIVER CIRRHOSIS,NCT02642874,Phase 3,0.024937504534170703,0.9750624954658292
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,OSTEOPOROSIS,NCT04550078,Not Applicable,0.1420032800146633,0.8579967199853367
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,_CALCIFEDIOL,MYOCARDIAL INFARCTION,NCT02548364,Phase 3,0.03892913476523136,0.9610708652347688
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03953261,Phase 2,0.14172053691889025,0.8582794630811097
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.15780257699303654,0.8421974230069634
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.5327748841624745,0.4672251158375256
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,ULCERATIVE COLITIS,NCT02277223,Phase 3,0.09481929603085328,0.9051807039691464
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,HIV INFECTION,NCT04425902,Phase 1,0.376700712446105,0.6232992875538951
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.2251945959555583,0.7748054040444419
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04011930,Phase 2,0.02402045189496985,0.97597954810503
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,ATOPIC DERMATITIS,NCT02537509,Phase 2,0.02145440918723488,0.978545590812765
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.08418799979207263,0.9158120002079272
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.005152193259835367,0.9948478067401646
CN(C)C(=N)NC(=N)N,_METFORMIN,HIV/AIDS,NCT04500678,Phase 2|Phase 3,0.03776806697495076,0.9622319330250492
CN(C)C(=N)NC(=N)N,_METFORMIN,DIABETIC RETINOPATHY,NCT02587741,Early Phase 1,0.0046100169005490865,0.9953899830994508
CN(C)C(=N)NC(=N)N,_METFORMIN,HEART FAILURE,NCT03331861,Phase 2,0.02379842567974403,0.9762015743202558
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS,NCT04068246,Early Phase 1,0.0008787182769703912,0.9991212817230296
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,NCT02246257,Not Applicable,0.0008787182769703912,0.9991212817230296
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,NEOPLASMS,NCT02964013,Phase 1,0.6620703699654388,0.3379296300345614
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,_PEMETREXED,CARCINOMA|NON-SMALL-CELL LUNG,NCT03952403,Phase 3,0.4942480263597129,0.5057519736402871
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.08026085193402671,0.9197391480659732
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,SEPSIS,NCT01784159,Phase 2,0.01988115163652815,0.9801188483634716
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.11598460054703827,0.8840153994529615
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.08026085193402671,0.9197391480659732
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,SEPSIS,NCT01784159,Phase 2,0.01988115163652815,0.9801188483634716
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.11598460054703827,0.8840153994529615
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,NEUROPATHIC PAIN,NCT01914042,Phase 2,0.2355507590441821,0.764449240955818
NC(N)=O,_UREA,HELICOBACTER PYLORI INFECTION,NCT04233684,Not Applicable,0.3161363111571378,0.6838636888428623
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,_ICOSAPENT_ETHYL,ALZHEIMER DISEASE,NCT02719327,Phase 2|Phase 3,0.4185633505863025,0.5814366494136975
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,SCHIZOPHRENIA,NCT04094207,Phase 1|Phase 2,0.12237530692934452,0.8776246930706555
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT02451774,Phase 2|Phase 3,0.11079557308457418,0.8892044269154258
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,BREAST CANCER,NCT02958852,Phase 2,0.02663381218899104,0.9733661878110088
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,_FEXOFENADINE,GASTROESOPHAGEAL REFLUX,NCT03425097,Phase 2,0.04108005854841963,0.9589199414515804
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,RHEUMATOID ARTHRITIS,NCT03770702,Phase 3,0.2890181947906257,0.7109818052093745
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,OBESITY,NCT03777215,Early Phase 1,0.3460416085112578,0.6539583914887421
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,MULTIPLE SCLEROSIS,NCT03161028,Phase 2,0.16705883728305326,0.8329411627169463
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,BREAST CANCER,NCT02897700,Phase 1,0.2647435439991034,0.7352564560008966
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,HIV INFECTION,NCT04425902,Phase 1,0.2752124654338945,0.7247875345661055
COCCc1ccc(OCC(O)CNC(C)C)cc1,_METOPROLOL,HIV INFECTION,NCT04425902,Phase 1,0.3339176392377172,0.6660823607622827
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,DYSPEPSIA,NCT02621359,Phase 3,0.1105082061959534,0.8894917938040465
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,HIV INFECTION,NCT04425902,Phase 1,0.2309237964487952,0.7690762035512045
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.001851796851796852,0.9981482031482032
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,HIV INFECTION,NCT04425902,Phase 1,0.17263543743954127,0.8273645625604585
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.001851796851796852,0.9981482031482032
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,ALZHEIMER DISEASE,NCT03991988,Phase 2,0.018991050277593062,0.9810089497224068
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.012748496940529831,0.98725150305947
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.12353044710509113,0.8764695528949088
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,HIV INFECTION,NCT04425902,Phase 1,0.2860695163537007,0.7139304836462991
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,FATIGUE,NCT04141696,Phase 1|Phase 2,0.15020600326301578,0.849793996736984
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,OVARIAN CANCER,NCT03532139,Phase 2,0.18461964829082667,0.8153803517091732
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,LYMPHOMA,NCT04514029,Early Phase 1,0.32437807255794565,0.6756219274420542
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,NCT02246257,Not Applicable,0.10549615713731272,0.8945038428626871
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,_EZETIMIBE,CHRONIC HEPATITIS C,NCT02971033,Phase 2,0.2746189333110198,0.7253810666889803
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,MYOCARDIAL INFARCTION,NCT03715998,Phase 2,0.1223940228900051,0.8776059771099947
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,PERIPHERAL NEUROPATHY,NCT03688633,Phase 2,0.16641702464326932,0.8335829753567303
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,BREAST CANCER,NCT03109990,Not Applicable,0.13447843632889822,0.8655215636711017
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,ALZHEIMER DISEASE,NCT04205539,Phase 1,0.3713672609373934,0.6286327390626065
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03129828,Phase 1|Phase 2,0.1154778933368891,0.8845221066631109
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,_BORTEZOMIB,ACUTE MYELOID LEUKEMIA,NCT04173585,Phase 2,0.05406398977746392,0.945936010222536
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,_CLOFARABINE,GRAFT VS HOST DISEASE,NCT03263767,Phase 2,0.6820175735455087,0.3179824264544913
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,NCT02246257,Not Applicable,0.05570883401194375,0.944291165988056
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ACUTE MYELOID LEUKEMIA,NCT02013648,Phase 3,0.3081524535910554,0.6918475464089446
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ALZHEIMER DISEASE,NCT04063124,Phase 1|Phase 2,0.4003352373712067,0.5996647626287932
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.34770815857201504,0.652291841427985
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,_PANOBINOSTAT,HIV INFECTION,NCT02471430,Phase 1|Phase 2,0.3093944891856927,0.6906055108143072
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,MULTIPLE MYELOMA,NCT03091257,Phase 1,0.5711762218108318,0.4288237781891681
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,_IDELALISIB,ACUTE LYMPHOBLASTIC LEUKEMIA,NCT03742323,Phase 1|Phase 2,0.7427295184204833,0.2572704815795167
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,BREAST CANCER,NCT03168074,Phase 2,0.52840683619986,0.4715931638001401
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,BREAST CANCER,NCT04298918,Phase 1|Phase 2,0.9671261482745304,0.032873851725469895
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MANTLE CELL LYMPHOMA,NCT03523975,Phase 1,0.9784597205780686,0.02154027942193142
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MYELODYSPLASTIC SYNDROME,NCT02942290,Phase 1,0.9596657945723844,0.04033420542761545
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,_LORLATINIB,ADVANCED CANCERS,NCT03726333,Phase 1,0.4303920785150957,0.5696079214849044
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,_COPANLISIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT04263584,Phase 2,0.8711396973803123,0.12886030261968784
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,BREAST CANCER,NCT04170465,Phase 2,0.09839411483971906,0.9016058851602808
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,HEART FAILURE,NCT03331861,Phase 2,0.15436823650162088,0.8456317634983789
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.16851631799425287,0.8314836820057468
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MANTLE CELL LYMPHOMA,NCT03891355,Phase 2,0.17517101287154574,0.8248289871284541
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MULTIPLE MYELOMA,NCT03989414,Phase 1|Phase 2,0.16891321739518436,0.8310867826048153
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,_CC-220,MULTIPLE MYELOMA,NCT02773030,Phase 1|Phase 2,0.6053665448776931,0.39463345512230696
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,_IXAZOMIB,MANTLE CELL LYMPHOMA,NCT03616782,Phase 2,0.3556776374228273,0.6443223625771723
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,_THALIDOMIDE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02733380,Phase 2,0.09910811316712602,0.900891886832874
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,_VINDESINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02767674,Phase 3,0.23718936683705497,0.7628106331629451
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03129828,Phase 1|Phase 2,0.14488983065871852,0.8551101693412814
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,PROSTATE CANCER,NCT02643667,Phase 1|Phase 2,0.3960971450352179,0.603902854964782
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,LYMPHOMA,NCT02436707,Phase 2,0.30927591217452965,0.6907240878254703
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,GRAFT VS HOST DISEASE,NCT04235036,Phase 2,0.4030987001608295,0.5969012998391705
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,NON-HODGKIN'S LYMPHOMA,NCT03198026,Phase 2,0.4030987001608295,0.5969012998391705
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,_DUVELISIB,PERIPHERAL T CELL LYMPHOMA,NCT03372057,Phase 2,0.9330231827966948,0.06697681720330521
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,BREAST NEOPLASM,NCT03295552,Phase 2,0.17496479498237275,0.8250352050176272
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,HODGKIN LYMPHOMA,NCT03250962,Phase 2,0.07196288472639881,0.9280371152736012
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,_DECITABINE,NON HODGKIN LYMPHOMA,NCT04337606,Phase 1|Phase 2,0.15722614946854846,0.8427738505314515
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT02753062,Phase 2,0.22611690021214675,0.7738830997878531
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,MULTIPLE MYELOMA,NCT04083898,Phase 1|Phase 2,0.2552051552147077,0.7447948447852923
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,DIFFUSE LARGE B-CELL LYMPHOMA,NCT02763319,Phase 2|Phase 3,0.14264615343094555,0.8573538465690543
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,PERIPHERAL T CELL LYMPHOMA,NCT04083495,Phase 2,0.38677847994035547,0.6132215200596446
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.02527636030106568,0.9747236396989344
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,"LYMPHOMA, T-CELL, CUTANEOUS",NCT03116659,Early Phase 1,0.2949542971475885,0.7050457028524114
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,INFERTILITY,NCT03824340,Not Applicable,0.017639467765809203,0.9823605322341906
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,_TOPIRAMATE,SCHIZOPHRENIA,NCT02808533,Not Applicable,0.1420452078519974,0.8579547921480024
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,PCOS,NCT04213677,Phase 3,0.04561207170818464,0.9543879282918156
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.04614149439424442,0.9538585056057556
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,ALZHEIMER DISEASE,NCT03801642,Phase 1|Phase 2,0.04614149439424442,0.9538585056057556
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,AGING,NCT04401904,Phase 1|Phase 2,0.04614149439424442,0.9538585056057556
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,_DICLOFENAC,BREAST CANCER,NCT04511832,Not Applicable,0.08042658227324731,0.9195734177267526
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,_CODEINE,CHRONIC HEART FAILURE,NCT04332536,Not Applicable,0.4790684025722428,0.5209315974277572
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,VASCULITIS,NCT03692416,Phase 3,0.07562470241489938,0.9243752975851006
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,_FLUCONAZOLE,CRYPTOCOCCAL MENINGITIS,NCT03945448,Phase 2|Phase 3,0.091469497809727,0.9085305021902728
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,_CIPROFLOXACIN,PNEUMONIA,NCT03177720,Phase 1,0.06183359135531151,0.9381664086446884
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,INFECTION,NCT03844776,Not Applicable,0.16452114787313324,0.8354788521268667
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,GLAUCOMA,NCT04052269,Phase 3,0.1896481803987804,0.8103518196012193
CCCC(CCC)C(=O)O,_VALPROIC_ACID,ACUTE MYELOID LEUKEMIA,NCT01369368,Phase 1|Phase 2,0.3051754597611325,0.6948245402388676
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,_CALCITONIN,MIGRAINE DISORDERS,NCT04019496,,0.33306013392189193,0.6669398660781077
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,_PYRIMETHAMINE,MYELODYSPLASTIC SYNDROME,NCT03057990,Phase 1,0.4049429972108765,0.5950570027891234
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,_SULFADOXINE,MALARIA IN PREGNANCY,NCT03998839,,0.1728437852286127,0.8271562147713871
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,SCHIZOPHRENIA,NCT04369391,Phase 1,0.3611814274123567,0.6388185725876433
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.30880622299404864,0.6911937770059512
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,_IMIPENEM,PNEUMONIA,NCT03177720,Phase 1,0.18120865557874385,0.8187913444212562
COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,_BEDAQUILINE,TUBERCULOSIS|HIV INFECTIONS,NCT02906007,Phase 1|Phase 2,0.4414542217749146,0.5585457782250852
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.170573979661344,0.8294260203386556
[Cl-].[Na+],_SODIUM_CHLORIDE,ALLERGIC ASTHMA,NCT04035109,Phase 1|Phase 2,0.19218426661192176,0.8078157333880782
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_BUDESONIDE,ACUTE ASTHMA,NCT04016220,Phase 1,0.007434892327172399,0.9925651076728276
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.18273656024281226,0.8172634397571875
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,INFECTION,NCT03844776,Not Applicable,0.21623539107478454,0.7837646089252154
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,LIVER CIRRHOSIS,NCT03005444,Not Applicable,0.2145461265014234,0.7854538734985766
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,TYPE 1 DIABETES,NCT03228732,Early Phase 1,0.1286861505385089,0.8713138494614907
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,DYSPEPSIA,NCT02621359,Phase 3,0.2425777429692217,0.7574222570307783
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT02067780,Phase 2,0.171974797396776,0.8280252026032237
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,_LAMIVUDINE,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT03528941,,0.0611853861568751,0.9388146138431248
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,HYPERTENSION,NCT02133872,Phase 1,0.8336200456461847,0.16637995435381525
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,OBESITY|INSULIN RESISTANCE,NCT03859583,Not Applicable,0.21980109854190652,0.7801989014580932
CC[C@@H](C(N)=O)N1CCCC1=O,_LEVETIRACETAM,SCHIZOPHRENIA,NCT02647437,Not Applicable,0.19697939733215172,0.803020602667848
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,ANXIETY,NCT02548559,Phase 2,0.5018882041355025,0.4981117958644977
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,_NITAZOXANIDE,DYSPEPSIA,NCT02621359,Phase 3,0.4661666799257528,0.5338333200742472
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,METASTATIC BREAST CANCER,NCT03982004,Phase 1,0.3937430672035512,0.6062569327964487
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,"LYMPHOMA, T-CELL, CUTANEOUS",NCT03116659,Early Phase 1,0.3884183157261416,0.6115816842738584
O=NN(CCCl)C(=O)NCCCl,_CARMUSTINE,DIFFUSE LARGE B CELL LYMPHOMA,NCT03072771,Phase 1,0.9954050673562074,0.004594932643792768
Oc1ncnc2[nH]ncc12,_ALLOPURINOL,CHRONIC KIDNEY DISEASE,NCT03990363,Phase 2,0.328281377408917,0.6717186225910825
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,MULTIPLE MYELOMA,NCT03406091,,0.31042315369956835,0.6895768463004314
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,"DIABETES MELLITUS, TYPE 1",NCT03182426,Phase 1|Phase 2,0.20415019795312825,0.7958498020468716
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT03736616,Phase 2,0.7411822900503925,0.2588177099496079
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,NON HODGKIN LYMPHOMA,NCT02180711,Phase 1|Phase 2,0.7647149187116452,0.2352850812883553
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,_ACALABRUTINIB,INFECTIOUS DISEASES,NCT04489797,Phase 1,0.7403636039661459,0.2596363960338542
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.3258397078039621,0.6741602921960379
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.2387291282081088,0.7612708717918913
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,_ETOPOSIDE_PHOSPHATE,LYMPHOMA,NCT02106988,Phase 2,0.6425141848172453,0.3574858151827551
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,HEART FAILURE,NCT02421341,Not Applicable,0.13118158145358644,0.8688184185464134
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,JUVENILE IDIOPATHIC ARTHRITIS,NCT04169828,Not Applicable,0.5623020995928346,0.4376979004071654
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,FATIGUE,NCT04141696,Phase 1|Phase 2,0.1662496695630998,0.8337503304369
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,THYROID DISEASES,NCT04471597,Not Applicable,0.08342600631041071,0.9165739936895893
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,ASTHMA IN CHILDREN,NCT04002362,Phase 2,0.27205706830097204,0.727942931699028
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PSORIASIS,NCT04117919,Phase 2,0.00822229502213812,0.991777704977862
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_TRIAMCINOLONE_ACETONIDE,ASTHMA IN CHILDREN,NCT04002362,Phase 2,0.5250549203104488,0.4749450796895512
O=C([O-])O.[Na+],_SODIUM_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.14640271366531998,0.8535972863346801
O=C(O)O,_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.2943626190869579,0.7056373809130421
CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,_CLEMASTINE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.4579884176972813,0.5420115823027186
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.12866649450169965,0.8713335054983001
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,ACUTE MYELOID LEUKEMIA,NCT02942758,Phase 2,0.06711394550353772,0.932886054496462
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,OBESITY,NCT03866408,Early Phase 1,0.09490978047155976,0.9050902195284404
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,GASTROPARESIS,NCT04300127,Early Phase 1,0.20185695855827332,0.7981430414417264
CN(C)/N=N/c1[nH]cnc1C(N)=O,_DACARBAZINE,HODGKIN LYMPHOMA,NCT03033914,Phase 1|Phase 2,0.3015598210181277,0.6984401789818719
O=S(=O)(O)CCS,_MESNA,LYMPHOMA,NCT02436707,Phase 2,0.26900071311048,0.7309992868895202
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,_MILNACIPRAN,DEPRESSION,NCT02783430,Phase 2|Phase 3,0.16559130889520646,0.8344086911047935
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,_MILNACIPRAN,NEUROPATHIC PAIN,NCT01914042,Phase 2,0.16559130889520646,0.8344086911047935
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,PAIN,NCT04034004,Early Phase 1,0.16661072390261988,0.8333892760973801
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,"DIABETES MELLITUS, TYPE 1",NCT03149770,Phase 2,0.16661072390261988,0.8333892760973801
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,_BUPIVACAINE_HYDROCHLORIDE,THYROID DISEASES,NCT04471597,Not Applicable,0.1794773737668663,0.8205226262331337
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,_TENOFOVIR_ALAFENAMIDE,HIV-1 INFECTION,NCT04301661,,0.18733012522486092,0.8126698747751391
COc1cc(CC(C)N)c(OC)cc1C,_DOM,STROKE,NCT03828851,Not Applicable,0.5650300041211928,0.4349699958788074
COc1cc(CC(C)N)c(OC)cc1C,_DOM,GASTROPARESIS,NCT03810287,Early Phase 1,0.6584844431971771,0.34151555680282314
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,_SOFOSBUVIR,HEPATITIS B INFECTION,NCT03312023,Phase 2,0.2579523082820248,0.7420476917179752
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,_LEDIPASVIR,HEPATITIS B INFECTION,NCT03312023,Phase 2,0.32838359020112423,0.6716164097988756
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],_SODIUM_THIOSULFATE,CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT00293475,Phase 1|Phase 2,0.7532656999523788,0.24673430004762184
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,_FAMOTIDINE,LYMPHOMA,NCT03647072,Phase 3,0.07524045443086573,0.9247595455691341
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,_FAMOTIDINE,EOSINOPHILIC ESOPHAGITIS,NCT04248712,Phase 2,0.11433912468798982,0.8856608753120101
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],_MAGNESIUM_CITRATE,DIABETIC NEPHROPATHY,NCT03824379,Phase 2,0.15455896944451014,0.8454410305554896
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,_BROMOCRIPTINE,OBESITY,NCT03525002,Phase 2,0.5916993573253793,0.4083006426746209
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,_LORATADINE,EOSINOPHILIC ESOPHAGITIS,NCT04248712,Phase 2,0.09574975934860606,0.9042502406513938
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,_CRIZOTINIB,NEOPLASMS,NCT03194893,Phase 3,0.4246348978544017,0.5753651021455982
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_APATINIB,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.21102497251330274,0.7889750274866971
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,_RIVOCERANIB,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.21102497251330274,0.7889750274866971
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,OVARIAN CANCER,NCT03763123,Phase 1,0.6722740318010387,0.3277259681989614
CN(C)CCC=C1c2ccccc2CCc2ccccc21,_AMITRIPTYLINE,GERD,NCT04292470,Not Applicable,0.3980123471604548,0.6019876528395453
CCN(CC)C(=S)SSC(=S)N(CC)CC,_DISULFIRAM,METASTATIC BREAST CANCER,NCT04265274,Phase 2,0.502991634949634,0.4970083650503661
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,TYPE 1 DIABETES,NCT04201496,Phase 1,0.27814783015507244,0.7218521698449274
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,CHRONIC KIDNEY DISEASE,NCT03594110,Phase 3,0.219260544813459,0.780739455186541
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,GESTATIONAL DIABETES,NCT03215069,Phase 3,0.215624430648948,0.784375569351052
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,_MARAVIROC,STROKE,NCT03172026,Phase 2|Phase 3,0.034722260416964315,0.9652777395830356
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.006344039663720629,0.9936559603362792
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.016009547212887342,0.9839904527871126
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.006344039663720629,0.9936559603362792
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.016009547212887342,0.9839904527871126
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,_MEGESTROL_ACETATE,BREAST CANCER,NCT03306472,Phase 2,0.1944330669598856,0.8055669330401143
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,_DOBUTAMINE,MYOCARDIAL INFARCTION,NCT03289728,Not Applicable,0.11205787548012702,0.8879421245198728
CN1CCN2c3ncccc3Cc3ccccc3C2C1,_MIRTAZAPINE,BREAST CANCER,NCT02336750,Phase 3,0.1508586636702492,0.8491413363297505
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,_TIVOZANIB,HEPATOCELLULAR CARCINOMA,NCT03970616,Phase 1|Phase 2,0.7333426366911945,0.2666573633088057
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,_ALPRAZOLAM,TYPE 1 DIABETES,NCT03635437,Phase 1|Phase 2,0.1555030851592501,0.8444969148407497
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,_ZOLPIDEM,PROSTATIC NEOPLASMS,NCT03436745,Phase 1,0.22911083160538956,0.7708891683946103
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,CENTRAL NERVOUS SYSTEM LYMPHOMA,NCT00293475,Phase 1|Phase 2,0.6510372110122284,0.3489627889877718
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,ALZHEIMER DISEASE,NCT02792257,Phase 2,0.0961493765402874,0.9038506234597125
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,_RUPATADINE,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.2416807747863974,0.7583192252136024
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,_UMBRALISIB,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT04016805,Phase 2,0.6455697442774063,0.3544302557225938
CC(=O)O,_ACETIC_ACID,ATOPIC DERMATITIS|ECZEMA,NCT03775590,Not Applicable,0.27257347416254346,0.7274265258374567
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,_BUSPIRONE,GASTROPARESIS,NCT03587142,Phase 2,0.16794958288334288,0.8320504171166572
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,_RIBAVIRIN,ACUTE MYELOID LEUKEMIA,NCT03760666,Phase 1|Phase 2,0.11689060966068933,0.8831093903393105
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,TYPE 2 DIABETES,NCT03758144,Not Applicable,0.1483183515741503,0.8516816484258493
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,_RIMIDUCID,MULTIPLE MYELOMA,NCT03288493,Phase 1|Phase 2,0.7403897273915108,0.2596102726084896
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,_LEFLUNOMIDE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.026368334004293868,0.973631665995706
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,_PARSACLISIB,LYMPHOMA,NCT03235544,Phase 2,0.7806964910494429,0.21930350895055736
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,_TUCIDINOSTAT,BREAST CANCER,NCT04465097,Phase 2,0.2716837353467886,0.7283162646532112
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,_TUCIDINOSTAT,DIFFUSE LARGE B-CELL LYMPHOMA,NCT04231448,Phase 3,0.27322924198832793,0.7267707580116719
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,BREAST CANCER,NCT03911453,Early Phase 1,0.6592819009988709,0.3407180990011293
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.6882200634559004,0.3117799365441
O=[As]O[As]=O,_ARSENIC_TRIOXIDE,HIV/AIDS,NCT03980665,Phase 1,0.4702002064049379,0.529799793595062
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,_TOFACITINIB,JUVENILE IDIOPATHIC ARTHRITIS,NCT01500551,Phase 3,0.172611462344177,0.8273885376558229
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,BURN,NCT03513406,Phase 3,0.2726217113514394,0.7273782886485606
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.05511048967181261,0.9448895103281872
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03843125,Phase 3,0.26549866711673953,0.7345013328832602
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,JUVENILE IDIOPATHIC ARTHRITIS,NCT03773978,Phase 3,0.26882061431653165,0.7311793856834682
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,ATOPIC DERMATITIS,NCT03952559,Phase 3,0.26882061431653165,0.7311793856834682
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.0785348381373829,0.9214651618626172
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,LIVER CIRRHOSIS,NCT03995251,Not Applicable,0.09028159053505258,0.9097184094649474
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT03910738,Phase 2,0.04053478022928072,0.9594652197707192
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_ENANTHATE,PROSTATE CANCER,NCT02090114,Phase 2,0.4669964937589334,0.5330035062410665
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_UNDECANOATE,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT03910738,Phase 2,0.2135850377685703,0.7864149622314295
CCCCCCCCCCC(=O)O,_UNDECANOATE,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT03910738,Phase 2,0.4785253269896104,0.5214746730103897
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,HEPATOCELLULAR CARCINOMA,NCT04258566,Phase 1,0.5235134649967075,0.4764865350032925
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,RHEUMATOID ARTHRITIS,NCT02680067,Phase 1,0.4858720267491489,0.5141279732508511
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,ENDOMETRIOSIS,NCT03950206,Not Applicable,0.1903282044035064,0.8096717955964935
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,_ATOVAQUONE,ACUTE MYELOID LEUKEMIA,NCT03568994,Early Phase 1,0.2357684586497407,0.7642315413502593
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,_BERBERINE,METABOLIC SYNDROME,NCT03976336,Not Applicable,0.1887468440413955,0.8112531559586043
O=[N+]([O-])[O-],_NITRATE,HEART FAILURE,NCT02840799,Phase 2,0.17335222937504205,0.8266477706249578
O=[N+]([O-])[O-],_NITRATE,ERECTILE DYSFUNCTION,NCT04116060,Not Applicable,0.21452974618399548,0.7854702538160044
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,_DONEPEZIL,"DIABETES MELLITUS, TYPE 2",NCT04507438,Phase 2,0.11535402148913815,0.8846459785108617
CC(=O)C(=O)O,_PYRUVATE,PROSTATE CANCER,NCT02913131,Phase 1|Phase 2,0.5051119148125839,0.4948880851874162
CC(=O)C(=O)O,_PYRUVATE,BREAST CANCER,NCT03121989,Phase 1,0.3288100051139453,0.6711899948860547
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,_PACRITINIB,BREAST CANCER,NCT04520269,Phase 1|Phase 2,0.6529352069979754,0.3470647930020246
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,_TERBUTALINE,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.12606489781745844,0.8739351021825414
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,_DANAZOL,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.3990774051811307,0.6009225948188691
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.10862932360375044,0.8913706763962495
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,_OXYMETAZOLINE,FECAL INCONTINENCE,NCT03529487,Phase 1,0.21488371439576232,0.7851162856042374
CN(C)CCC=C1c2ccccc2COc2ccccc21,_DOXEPIN,BREAST CANCER,NCT02447211,Phase 2,0.16342340849727224,0.8365765915027277
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,_DOMPERIDONE,GASTROPARESIS,NCT03810287,Early Phase 1,0.4978214749840223,0.5021785250159777
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,_ALBUTEROL_SULFATE,ASTHMA,NCT03847896,Phase 3,0.20261873382359027,0.7973812661764095
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,SCHIZOPHRENIA,NCT04531982,Phase 3,0.27626071089584764,0.7237392891041522
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,_TOMIVOSERTIB,BREAST CANCER,NCT04261218,Phase 1,0.777839446002896,0.2221605539971043
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,_FOSTAMATINIB,OVARIAN CANCER,NCT03246074,Phase 1,0.7714674351110787,0.2285325648889214
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,_SEMAGLUTIDE,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.24314302100435956,0.7568569789956403
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,_SAPACITABINE,BREAST CANCER,NCT03641755,Phase 1|Phase 2,0.8475777725549049,0.15242222744509554
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,_SALSALATE,PCOS,NCT03229408,Phase 2,0.16995123212544352,0.8300487678745566
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,PAIN,NCT04313179,Not Applicable,0.6049233549060075,0.3950766450939927
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,"DIABETES MELLITUS, TYPE 1",NCT03436992,Not Applicable,0.2116811565758702,0.7883188434241297
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,PAIN,NCT04132609,Not Applicable,0.6568986230553684,0.3431013769446318
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,NICOTINE DEPENDENCE,NCT03325777,Not Applicable,0.6282457034832939,0.3717542965167062
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,ANXIETY,NCT04245501,Not Applicable,0.6103429761453947,0.3896570238546053
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,_GLUCAGON,INSULIN SECRETION,NCT04347252,Phase 1,0.268174701479082,0.7318252985209177
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,_GLUCAGON,INSULIN SENSITIVITY,NCT04300049,Not Applicable,0.3725837738700449,0.6274162261299548
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,_HESPERIDIN,METABOLIC SYNDROME,NCT03734874,Not Applicable,0.5353985615707639,0.464601438429236
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,_FENRETINIDE,PERIPHERAL T CELL LYMPHOMA,NCT02495415,Phase 2,0.7141229078686657,0.2858770921313344
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,_TENALISIB,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",NCT04204057,Phase 2,0.7382104518721132,0.2617895481278868
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,_SELICICLIB,CUSHING DISEASE,NCT03774446,Phase 2,0.6304828251090934,0.3695171748909065
COc1cc(C(=O)c2c(C)oc3c(OP(=O)(O)O)c(OC)ccc23)cc(OC)c1OC,_BNC105,CHRONIC LYMPHOCYTIC LEUKEMIA,NCT03454165,Phase 1,0.6288085878005404,0.3711914121994597
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,_BAZEDOXIFENE,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT04002934,Phase 2,0.2557063642184064,0.7442936357815934
O=[O+][O-],_OZONE,ISCHEMIC HEART DISEASE,NCT03660657,Phase 2|Phase 3,0.18694613369062268,0.8130538663093771
C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,_EVOBRUTINIB,RELAPSING MULTIPLE SCLEROSIS,NCT04338061,Phase 3,0.7217414667829921,0.2782585332170077
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.13821092089163425,0.8617890791083657
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,_VILANTEROL,PHARMACOKINETICS,NCT03739294,Phase 2,0.21522947882446616,0.7847705211755341
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.18620470826273952,0.8137952917372603
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,_BICTEGRAVIR,HIV/AIDS,NCT03789968,,0.1393575571441336,0.8606424428558662
Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1,_SUVOREXANT,NICOTINE DEPENDENCE,NCT03999099,Phase 1,0.2494658155597595,0.7505341844402404
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,_IMETELSTAT,MYELODYSPLASTIC SYNDROME,NCT02598661,Phase 2|Phase 3,0.6357943139961832,0.3642056860038171
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,_DANTROLENE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.5421354965144681,0.4578645034855319
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,SCHIZOPHRENIA,NCT03817502,Phase 3,0.3614369323578269,0.6385630676421732
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,_LASMIDITAN,MIGRAINE DISORDERS,NCT04396574,Phase 3,0.4110270382054699,0.58897296179453
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.5255488502995491,0.4744511497004508
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,METASTATIC BREAST CANCER,NCT03238196,Phase 1,0.6241354026117581,0.3758645973882421
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.5503778642588265,0.4496221357411737
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,_ERAVACYCLINE,BACTERIAL INFECTIONS,NCT03696550,Phase 1,0.4324829601340714,0.5675170398659285
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.4106053450824586,0.5893946549175414
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,ACUTE MYELOID LEUKEMIA,NCT04075747,Phase 1,0.4644715619860586,0.5355284380139413
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.4285945827086765,0.5714054172913234
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,DIFFUSE LARGE B CELL LYMPHOMA,NCT04460248,Phase 2,0.33332890908260804,0.6666710909173921
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,WALDENSTRÃ–M MACROGLOBULINEMIA,NCT04463953,Phase 2,0.3081118571528021,0.6918881428471977
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ATOPIC DERMATITIS,NCT03569293,Phase 3,0.3597536074469161,0.6402463925530839
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,JUVENILE IDIOPATHIC ARTHRITIS,NCT03725007,Phase 1,0.4465268758290104,0.5534731241709897
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT04451772,Phase 2,0.3752396639265537,0.6247603360734463
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ULCERATIVE COLITIS,NCT03006068,Phase 3,0.3718428413569679,0.6281571586430322
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,_UBROGEPANT,MIGRAINE DISORDERS,NCT04492020,Phase 3,0.4829924826408262,0.5170075173591738
